Evidence map›Paper›PMID 41808714›Full record

ArticleTranslational lung cancer research2026

Analysis of clinical and genomic features in a Chinese cohort with

Meng Zhang, Yi Feng, Xue Du, Changda Qu, Meizhu Meng, Meiying Ye, Min Liang, Ziran Yang, Wenjuan Gong, Xingyu Ma and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Meng ZhangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.ORCID https://orcid.org/0000-0003-1653-9230
Yi FengState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Xue DuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Changda QuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Meizhu MengState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Meiying YeState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Min LiangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Ziran YangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Wenjuan GongState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Xingyu MaState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Jialiang GuoState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Wenmei LiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.
Shuqin JiaState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Center for Molecular Diagnostics, Peking University Cancer Hospital & Institute, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neuregulin 1 ( Methods: We retrospectively analyzed next-generation sequencing (NGS) data from 3,132 Chinese NSCLC patients and investigated Results: Conclusions: This study revealed the distinct clinicogenomic landscapes of

Indexed as

co-mutationsfusionmutationsNeuregulin 1 (NRG1)non-small cell lung cancer (NSCLC)

Identifiers

PMID41808714
PMCPMC12969179

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.